Effects of calcium channel blocker on responses of blood flow, function, arrhythmias, and extent of infarction following reperfusion in conscious baboons.
Two groups of chronically instrumented, conscious baboons were studied. The effects of coronary artery occlusion for 3 hours and reperfusion for 1 week were examined on measurements of left ventricular function, ischemic-zone wall thickness, regional myocardial blood flow, arrhythmias, and extent of necrosis. The experimental group of animals (n = 7) was treated with the calcium channel blocker nisoldipine (0.1 microgram/kg/min) from 1 hour after coronary occlusion to 3 hours after coronary reperfusion. The control group (n = 6) received the vehicle (n = 4) or saline (n = 2). The effects of coronary artery occlusion and reperfusion on arterial pressure, left ventricular systolic pressure, heart rate, and left ventricular dP/dt were similar in both groups. Systolic wall thickening was reversed to paradoxical wall thinning during occlusion in both groups, and there was no recovery to systolic wall thickening over the 1-week period in either group. There were differences in regional blood flow; during coronary artery occlusion, nisoldipine increased blood flow significantly in the endocardium and epicardium of nonischemic and ischemic zones. There was a major difference in the number of arrhythmic beats per minute on reperfusion; during reperfusion, the number of arrhythmias rose markedly in the vehicle-treated group but actually fell in the nisoldipine-treated group. The size of areas at risk, infarcts, infarcts related to the area at risk, and amount of total creatine kinase (CK) and MB-CK appearing in blood were not significantly different in the two groups. Thus, in the conscious baboon, nisoldipine administered 1 hour after coronary artery occlusion exerted a marked effect in diminishing reperfusion-induced arrhythmias and improved blood flow to the ischemic zone during occlusion but did not salvage ischemic tissue.
Vatner
S F
SF
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Patrick
T A
TA
Knight
D R
DR
Manders
W T
WT
Fallon
J T
JT
D000818:Animals; D001145:Arrhythmias, Cardiac / Q000503:physiopathology*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003326:Coronary Circulation; D003331:Coronary Vessels; D003402:Creatine Kinase / Q000032:analysis; D006439:Hemodynamics; D007527:Isoenzymes; D008026:Ligation; D009203:Myocardial Infarction / Q000503:physiopathology*; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology; D015737:Nisoldipine; D010215:Papio; D010477:Perfusion; D012039:Regional Blood Flow / Q000187:drug effects
D002121:Calcium Channel Blockers; D007527:Isoenzymes; D015737:Nisoldipine; D003402:Creatine Kinase; D009543:Nifedipine